

Fei-Li Zhao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/133824/publications.pdf>

Version: 2024-02-01

18
papers

363
citations

933447

10
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

633
citing authors

#	ARTICLE	IF	CITATIONS
1	Psychometric Evaluation of the Mandarin HeartQoL Health-Related Quality of Life Questionnaire Among Patients With Ischemic Heart Disease in China. <i>Value in Health Regional Issues</i> , 2022, 31, 53-60.	1.2	2
2	Discrepancies between proxy estimates and patient reported, health related, quality of life: minding the gap between patient and clinician perceptions in heart failure. <i>Quality of Life Research</i> , 2021, 30, 1049-1059.	3.1	3
3	Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples. <i>PLoS ONE</i> , 2016, 11, e0147169.	2.5	10
4	Prevention of postpartum haemorrhage: cost consequences analysis of misoprostol in low-resource settings. <i>BMC Pregnancy and Childbirth</i> , 2015, 15, 305.	2.4	8
5	Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis of Randomized Controlled Trials. <i>Value in Health Regional Issues</i> , 2015, 6, 22-32.	1.2	4
6	Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 156.	2.4	57
7	Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis. <i>Pharmacoeconomics</i> , 2013, 31, 501-508.	3.3	24
8	Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: A meta-analysis of randomized placebo-controlled trials. <i>Epilepsy Research</i> , 2013, 103, 31-44.	1.6	31
9	Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?. <i>Value in Health Regional Issues</i> , 2013, 2, 152-159.	1.2	4
10	Clinical pathways for primary care: effects on professional practice, patient outcomes, and costs. <i>The Cochrane Library</i> , 2013, , .	2.8	13
11	Statin is a Reasonable Treatment Option for Patients with Polycystic Ovary Syndrome: a Meta-analysis of Randomized Controlled Trials. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2012, 120, 367-375.	1.2	48
12	COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 436-444.	0.5	24
13	Willingness to Pay per Quality-Adjusted Life Year: Is One Threshold Enough for Decision-Making?. <i>Medical Care</i> , 2011, 49, 267-272.	2.4	51
14	Health-related quality of life in Chinese patients with chronic prostatitis/chronic pelvic pain syndrome. <i>Quality of Life Research</i> , 2010, 19, 1273-1283.	3.1	15
15	Validation and Comparison of EuroQol and Short Form 6D in Chronic Prostatitis Patients. <i>Value in Health</i> , 2010, 13, 649-656.	0.3	47
16	Monocyte-Mediated Rotenone Neurotoxicity towards Human Neuroblastoma SH-SY5Y: Role of Mitogen-Activated Protein Kinases. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 1372-1377.	1.4	6
17	Potentiation of Adenosine A1 Receptor Agonist CPA-Induced Antinociception by Paeoniflorin in Mice. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 1630-1633.	1.4	13
18	Down regulation of cyclooxygenase-2 is involved in delayed neuro-protection by ischemic preconditioning in rats. <i>Acta Pharmacologica Sinica</i> , 2005, 26, 441-446.	6.1	3